argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

Core Insights - Argenx SE presented new data on empasiprubart and VYVGART® Hytrulo at the 2024 Peripheral Nerve Society Annual Meeting, highlighting their potential to improve treatment outcomes for patients with multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyneuropathy (CIDP) [2][3] Group 1: Empasiprubart for MMN - The Phase 2 ARDA study data supports empasiprubart as a novel treatment option for MMN, showing a 91% reduction in the risk of IVIg retreatment compared to placebo [4][10] - Empasiprubart demonstrated improvements in grip and muscle strength, enhancing patients' ability to perform daily activities [4] - The treatment was well-tolerated, with most adverse events being mild or moderate [4][13] Group 2: VYVGART Hytrulo for CIDP - VYVGART Hytrulo received FDA approval on June 21, 2024, as a safe and effective treatment for CIDP, showing a 61% reduction in the risk of relapse compared to placebo [5][7] - The ADHERE trial demonstrated sustained functional benefits across all disease scores, with 99% of participants opting for the open-label extension study [5][6] - Patients treated with VYVGART Hytrulo maintained functional improvements, while placebo patients experienced clinically meaningful worsening [6][7] Group 3: Company Overview - Argenx is focused on developing innovative therapies for severe autoimmune diseases, aiming to transform treatment outcomes and reduce the risk of relapse and disability [3][23] - The company is advancing a pipeline of antibody-based medicines, including empasiprubart and VYVGART Hytrulo, to address unmet medical needs in MMN and CIDP [3][23]